Clinical trial · Observational
The Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China
A Multi-center Study to Observe Five-year Outcomes of the Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China (The Second Stage of DTCC)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
* To find out the gap between real-world clinical practice and guideline recommendations in initial management of DTC patients * To observe the characteristics of patients who achieved and did not achieve TSH target value after five year follow-up * To assess response to initial therapy in patients who undergo total or neartotal thyroidectomy and RAI remnant ablation after five year follow-up (according to an modified dynamic risk stratification system) * To observe the recurrence status after five year follow-up
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Differentiated Thyroid Cancer | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Group1
- description
- About 1400 DTC patients with more than 5 years long-term follow-up from the date of signing the informed consent form (ICF) in DTCC 1st to signing ICF in DTCC 2nd will be collected data retrospectively.
Primary outcomes (1)
- measure
- recurrence rate
- timeFrame
- five year
- description
- Five-year accumulated recurrence rate
Secondary outcomes (7)
- measure
- Disease-free survival (DFS)
- timeFrame
- five year
- description
- Evaluated from the date of first-time thyroidectomy to the first to the progression date or death related to disease progression, whichever occurs first
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria:
\- Patients who had been recruited into DTCC 1st study will be enrolled.
Exclusion Criteria:
* Other malignant tumors;
* Severe organ damage such as heart failure of New York Heart Association classes III-IV, liver failure, respiratory failure, renal failure, etc.;
* Medical or psychological condition that would not permit the patient to complete the study or sign the informed consent; ④ Legal incapacity or limited legal capacity; ⑤ Unwilling to be followed upReferences
Publications (0)
Data not yet available